Optimising market access for rare disease products: insights from Craig Caceci

The complexity of bringing a rare disease product to market

In Craig’s experience, organisations working on rare and orphan disease specialty products are typically “very lean” companies with small workforces. The complexity of bringing a specialty pharmaceutical product to the marketplace may mean these companies struggle with the nuances that have to be accommodated, often simultaneously, before a product is launched.

To read more, click here.